APG-1387 clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses APG-1387 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- APG-1387 for Injection
- 4
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses APG-1387 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsTerminatedPhase 1/2Ascentage Pharma Group Inc.NCT04284488Written as APG-1387 for Injection
- APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaTerminatedPhase 1/2Ascentage Pharma Group Inc.NCT04643405Written as APG-1387 for Injection
- APG-1387 in Patients With Advanced Solid Tumors or Hematologic MalignanciesCompletedPhase 1Ascentage Pharma Group Inc.NCT03386526Written as APG-1387 for Injection
- APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BCompletedPhase 1Ascentage Pharma Group Inc.NCT03585322Written as APG-1387 for Injection
Given beside what is tested · 1 — APG-1387 is usual care or a partner of the new treatment
Codes
What other systems call APG-1387 · ClinicalTrials.gg INT000741
- MeSH (NLM) C000621546APG-1387One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621546 | APG-1387 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.